Edgestream Partners, L.P. Cytokinetics Inc Transaction History
Edgestream Partners, L.P.
- $2.88 Billion
- Q1 2025
A detailed history of Edgestream Partners, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 18,216 shares of CYTK stock, worth $584,369. This represents 0.03% of its overall portfolio holdings.
Number of Shares
18,216Holding current value
$584,369% of portfolio
0.03%Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$471 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$380 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$319 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$256 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$195 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.02B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...